STOCK TITAN

Kenneth Griffin’s Citadel Adds 4.8M Cabaletta Bio Shares, Tops 5%

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Cabaletta Bio (CABA) filed a Schedule 13G disclosing that Citadel Advisors LLC, Citadel Securities LLC, related entities and founder Kenneth Griffin collectively own 4,818,560 common shares, or approximately 5.2 % of the company’s 92.94 million shares outstanding.

Citadel Advisors–managed funds hold 4,687,280 shares, while market-making affiliate Citadel Securities holds 131,280 shares. All voting and dispositive power is reported as shared; none of the reporting persons has sole authority. The 5 % threshold was reached on 12 June 2025, triggering the filing. No additional financial results, risk factors, or strategic initiatives are included.

Positive

  • Citadel affiliates and Kenneth Griffin disclosed a 5.2 % stake (4.82 million shares) in Cabaletta Bio, introducing a high-profile institutional holder.

Negative

  • None.

Insights

TL;DR: Citadel now holds 5.2 % of CABA; passive stake, limited immediate impact.

Citadel Advisors and affiliated vehicles have crossed the 5 % beneficial-ownership line, requiring this Schedule 13G. The filing is made under Rule 13d-1(c), indicating a passive, non-activist position. All 4.82 million shares are subject to shared voting and dispositive power, suggesting coordinated but not unilateral decision-making. While the entrance of a sophisticated hedge fund may improve trading liquidity and spark investor attention, the document contains no plans for operational or governance changes. Consequently, the stake is noteworthy but does not materially alter Cabaletta Bio’s near-term fundamentals or control structure.

TL;DR: Governance framework unchanged; monitor for any shift to 13D.

Schedule 13G signifies a passive ownership intent. The group’s 5.2 % holding is below thresholds that typically secure board seats or trigger anti-takeover provisions. Zero sole voting power means no single entity can act independently, limiting influence on strategic decisions. Should the group increase its position or convert to a Schedule 13D, governance dynamics would warrant reassessment. For now, the filing is informational rather than transformational, keeping corporate control firmly with existing management and shareholders.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentages reported in this Schedule 13G are based upon 92,943,101 Shares outstanding comprised of (i) 89,943,101 Shares outstanding as of immediately following the issuer's public offering (according to the issuer's Prospectus Supplement as filed with the Securities and Exchange Commission on June 12, 2025), and (ii) 3,000,000 Shares issuable upon conversion of certain warrants held by affiliates of the reporting persons. Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on June 20, 2025.


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Citadel Advisors LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel Advisors Holdings LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel Securities LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel Securities Group LP
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Citadel Securities GP LLC
Signature:/s/ Seth Levy
Name/Title:Seth Levy, Authorized Signatory
Date:06/20/2025
Kenneth Griffin
Signature:/s/ Seth Levy
Name/Title:Seth Levy, attorney-in-fact*
Date:06/20/2025

Comments accompanying signature: * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.
Exhibit Information

Exhibit 99.1 - Joint Filing Agreement

FAQ

How many Cabaletta Bio (CABA) shares did Citadel entities report owning?

The Schedule 13G states Citadel-managed funds hold 4,687,280 shares, with shared voting and dispositive power.

What percentage of Cabaletta Bio’s outstanding stock does Citadel’s position represent?

Citadel affiliates reported ownership of approximately 5.0 %; including Kenneth Griffin’s aggregated amount, the stake is 5.2 %.

Who is identified as the ultimate controlling person in the 13G filing?

The filing names Kenneth Griffin as the control person with a beneficial interest in 4,818,560 shares.

Did any Citadel entity report sole voting power over CABA shares?

No. Each reporting person disclosed 0 shares of sole voting power; all authority is shared.

What date triggered the Schedule 13G requirement for Cabaletta Bio?

The event date is June 12, 2025, when the ownership threshold exceeded 5 %.
Cabaletta Bio, Inc.

NASDAQ:CABA

CABA Rankings

CABA Latest News

CABA Latest SEC Filings

CABA Stock Data

200.23M
94.75M
1.65%
79.78%
6.37%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
PHILADELPHIA